<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2221-2434</journal-id>
<journal-title><![CDATA[Revista Finlay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Finlay]]></abbrev-journal-title>
<issn>2221-2434</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos. Centro Provincial de información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2221-24342020000300259</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización del cáncer de mama triple negativo]]></article-title>
<article-title xml:lang="en"><![CDATA[Characterization of Triple Negative Breast Cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Heredia Martínez]]></surname>
<given-names><![CDATA[Bernardo Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Fernández]]></surname>
<given-names><![CDATA[Hailyn]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Universitario Dr. Gustavo Aldereguía Lima  ]]></institution>
<addr-line><![CDATA[Cienfuegos ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Docente Celestino Hernández Robau  ]]></institution>
<addr-line><![CDATA[Villa Clara ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>10</volume>
<numero>3</numero>
<fpage>259</fpage>
<lpage>268</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2221-24342020000300259&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2221-24342020000300259&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2221-24342020000300259&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento:  el cáncer de mama triple negativo constituye un problema de salud pública, por su elevada morbilidad y mortalidad.  Objetivo:  caracterizar las pacientes diagnosticadas con cáncer de mama triple negativo atendidas en el Servicio de Oncología del Hospital Universitario Docente Celestino Hernández Robau en el período 2015- 2016.  Método:  se realizó un estudio descriptivo de corte transversal. El universo correspondió a 59 pacientes diagnosticadas con cáncer de mama triple negativo con confirmación histológica. Se consideraron las variables: edad, color de la piel, variante histológica, tamaño tumoral, estado ganglionar, invasión vascular y linfática, grado histológico y nuclear, etapas clínicas, tratamiento, tipo y tiempo de aparición de las metástasis. La información recopilada se procesó por medio del programa estadístico IBM SPSS versión 21. Fueron utilizados de la estadística descriptiva las distribuciones de frecuencia y porcentaje. Los resultados fueron expresados mediante tablas.  Resultados:  el grupo etáreo predominante fue el de 60 y más años, el color de la piel blanca, el diagnóstico histológico más frecuente fue el carcinoma ductal infiltrante, prevaleció la etapa clínica II, predominó la no afectación de ganglios axilares y la no invasión vascular y linfática, las metástasis diagnosticadas que predominaron fueron las viscerales.  Conclusiones:  predominó la edad de 60 años y más y el carcinoma ductal infiltrante, el tamaño del tumor, grado histológico y grado nuclear constituyen factores pronósticos importantes para el diagnóstico y tratamiento del cáncer de mama triple negativo. Al término del estudio el 55,9 % de las pacientes estaban vivas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  triple negative breast cancer constitutes a public health problem due to its high morbidity and mortality.  Objective:  to characterize the patients diagnosed with triple negative breast cancer treated at the Oncology Service of the Celestino Hernández Robau University Hospital in the period 2015-2016.  Method: a descriptive cross-sectional study was carried out. The universe corresponded to 59 patients diagnosed with histological confirmed triple negative breast cancer. The variables were considered: age, skin color, histological variant, tumor size, lymph node status, vascular and lymphatic invasion, histological grade and clinical nucleo-stages, treatment, type and time of appearance of metastases. The information collected was processed through the statistical program IBM SPSS version 21. The frequency and percentage distributions were used from descriptive statistics. The results were expressed by charts.  Results:  the predominant age group was 60 and over, white skin color, the most frequent histological diagnosis was infiltrating ductal carcinoma, clinical stage II prevailed, there was no involvement of axillary lymph nodes or vascular and lymphatic invasion, the diagnosed metastases that the visceral ones predominated.  Conclusions:  the age of 60 years and older prevailed and infiltrating ductal carcinoma, tumor size, histological grade and nuclear grade are important prognostic factors for the diagnosis and treatment of triple negative breast cancer. At the end of the study, the 55,9 % of the patients were alive.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[carcinoma]]></kwd>
<kwd lng="es"><![CDATA[neoplasias inflamatorias de la mama]]></kwd>
<kwd lng="es"><![CDATA[mujer]]></kwd>
<kwd lng="en"><![CDATA[carcinoma]]></kwd>
<kwd lng="en"><![CDATA[inflammatory breast neoplasms]]></kwd>
<kwd lng="en"><![CDATA[women]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Grupo Español de Investigación en Cáncer de Mama</collab>
<source><![CDATA[Proyecto El Álamo III. Encuesta de evolución de pacientes con cáncer de mama en hospitales del grupo GEICAM 1998-2001]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[GEICAM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quirós]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia a 5 años de pacientes con cáncer de mama triple negativo]]></article-title>
<source><![CDATA[Med Leg Costa Rica]]></source>
<year>2017</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maffuz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Labastida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sherwell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ruvalcaba]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Tenorio]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia de pacientes con cáncer de mama. Análisis por factores pronósticos, clínicos y patológicos.]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2016</year>
<volume>84</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaharia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama triple negativo: una enfermedad de difícil diagnóstico y tratamiento]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Pública]]></source>
<year>2013</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud. Guía Clínica</collab>
<source><![CDATA[Cáncer de mama]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Santiago ]]></publisher-loc>
<publisher-name><![CDATA[Minsal, Chile]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dent]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Trudeau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pritchard]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Sawka]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple-negative breast cancer clinical features and patterns of recurrence]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2007</year>
<volume>13</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1-15</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Programa Integral para el Control del Cáncer en Cuba]]></source>
<year>2013</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Junceda]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cáncer de mama]]></source>
<year>1988</year>
<publisher-loc><![CDATA[Oviedo ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Oviedo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duque]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pesci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Guida]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínico patológicas del cáncer de mama. Experiencia de cinco años en una población de Venezuela.]]></article-title>
<source><![CDATA[Rev Venez Oncol]]></source>
<year>2018</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Villarreal]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Docetaxel en cáncer de mama metastásico multitratado]]></article-title>
<source><![CDATA[Gaceta Mex Oncol]]></source>
<year>2016</year>
<volume>15</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Armas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ropero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia del HER2 en el Cáncer de Mama en Cuba]]></article-title>
<source><![CDATA[Rev Cancerol]]></source>
<year>2009</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[La Cruz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia en pacientes con cáncer de mama triple negativo]]></article-title>
<source><![CDATA[Rev Venez Oncol]]></source>
<year>2012</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Romo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama triple negativo: frecuencia y características en el Hospital Ángeles Pedregal]]></article-title>
<source><![CDATA[Acta Méd Grupo Ángeles]]></source>
<year>2017</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casimo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arra]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Gentila]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Stigliano]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características imagenológicas del Cáncer de Mama Triple Negativo]]></article-title>
<source><![CDATA[Rev Argent Mastol]]></source>
<year>2018</year>
<volume>37</volume>
<numero>134</numero>
<issue>134</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Villaseñor]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer de mama triple negativo. Experiencia en pacientes del Incan]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Mexico DF ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Cancerología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horvath]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bañuelos]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gallegos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Galleguillos]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer mamario triple negativo ¿Cómo se ve en imágenes?]]></article-title>
<source><![CDATA[Rev Chil Radiol]]></source>
<year>2012</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amores]]></surname>
<given-names><![CDATA[AI.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cáncer de mama triple negativo con sus características mamográficas y ecográficas y factores asociados. SOLCA-Cuenca 2009-2016]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Cuenca ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Cuenca]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donker]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Tienhoven]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Straver]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Meijnen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS) a randomized, multicenter, open-label, phase 3 non-inferiority trial]]></article-title>
<collab>Van de Velde CJH.Mansel RE</collab>
<source><![CDATA[Lancet Oncol]]></source>
<year>2014</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1303-10</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mallma]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Veliz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Enríquez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Abugattas]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Mas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Neciosup]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influencia del tiempo de inicio de la quimioterapia adyuvante en el desenlace clínico en el cáncer de mama triple negativo]]></article-title>
<source><![CDATA[Carcinos]]></source>
<year>2016</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<source><![CDATA[Echavarría I. Identificación de predictores de respuesta a quimioterapia neoadyuvante con carboplatino-docetaxel en pacientes con cáncer de mama triple negativo]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Complutense de Madrid]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howlader]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Altekruse]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[VW]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ries]]></surname>
<given-names><![CDATA[LAG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2014</year>
<volume>106</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>55</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brenes]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama triple negativo en estadios tempranos: Perfil clínico y anatomopatológico]]></article-title>
<source><![CDATA[Rev Méd Costa Rica Centroam]]></source>
<year>2015</year>
<volume>72</volume>
<numero>614</numero>
<issue>614</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilagran M]]></surname>
<given-names><![CDATA[Sentís M]]></given-names>
</name>
<name>
<surname><![CDATA[Riego J]]></surname>
<given-names><![CDATA[Andreu FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dalmau E]]></surname>
<given-names><![CDATA[Planas]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma de mama triple negativo. Heterogeneidad inmunofenotípica y en el comportamiento farmacocinético]]></article-title>
<source><![CDATA[Radiología]]></source>
<year>2016</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnedo]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Análisis de sobrevida relacionada con factores pronósticos en mujeres con cáncer de mama tratadas en un centro cancerológico de la ciudad de Barranquilla 2011-2016]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Barranquilla ]]></publisher-loc>
<publisher-name><![CDATA[Universidad del Norte]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyman]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Somerfield]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Bosserman]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Weaver]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sentinel lymph node biopsy for patients with early-stage breast cancer American Society of Clinical Oncology clinical practice guideline update]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2017</year>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>561-4</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyman]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Temin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Edge]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Weaver]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1365:83</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orban]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Ulloa]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Gon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchotena]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama Triple Negativo: evaluación de características clínico-patológicas y factores pronósticos.]]></article-title>
<source><![CDATA[Rev Argent Mastol]]></source>
<year>2017</year>
<volume>36</volume>
<numero>130</numero>
<issue>130</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
